Literature DB >> 18079726

Silencing of mammalian genes by tetracycline-inducible shRNA expression.

Sven Kappel1, Yves Matthess, Manfred Kaufmann, Klaus Strebhardt.   

Abstract

Conditional gene silencing in mammalian cells, via the controlled expression of short hairpin RNAs (shRNAs), is an effective method for studying gene function, particularly if the gene is essential for cell survival or development. Here we describe a simple and rapid protocol for the generation of tetracycline (Tet)-inducible vectors that express shRNAs in a time- and dosage-dependent manner. Tet-operator (TetO) sequences responsive to occupation by the Tet-repressor (TetR) were inserted at alternative positions within the wild-type H1 promoter and cloned into a eukaryotic expression vector. Additional cloning sites downstream of the promoter enable the insertion of shRNA sequences. This Tet-inducible shRNA expression system can be used for both transient and stable RNA interference (RNAi) approaches to control gene function in a spatiotemporal fashion. The entire protocol (preparation of constructs, generation of stable cell lines and functional analysis) can be completed in 3 months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079726     DOI: 10.1038/nprot.2007.458

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  20 in total

1.  Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach.

Authors:  Onur Tokgun; Francesco Paolo Fiorentino; Pervin Elvan Tokgun; Jun Yokota; Hakan Akca
Journal:  Mol Biotechnol       Date:  2017-06       Impact factor: 2.695

2.  Promoter cross-talk affects the inducible expression of intronic shRNAs from the tetracycline response element.

Authors:  Seong Kyun Park; Byung Joon Hwang; Yun Kee
Journal:  Genes Genomics       Date:  2019-01-17       Impact factor: 1.839

3.  Biomolecular engineering of intracellular switches in eukaryotes.

Authors:  M K Pastuszka; J A Mackay
Journal:  J Drug Deliv Sci Technol       Date:  2010-05       Impact factor: 3.981

4.  Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells.

Authors:  Junhao Lin; Yuchen Liu; Yonghao Zhan; Chengle Zhuang; Li Liu; Xing Fu; Wen Xu; Jianfa Li; Mingwei Chen; Zhiming Cai; Weiren Huang
Journal:  Tumour Biol       Date:  2015-10-01

5.  Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity.

Authors:  Yves Matthess; Monika Raab; Mourad Sanhaji; Inna N Lavrik; Klaus Strebhardt
Journal:  Mol Cell Biol       Date:  2010-10-11       Impact factor: 4.272

6.  MicroRNAs and cancer therapeutics.

Authors:  Man Lung Yeung; Kuan-Teh Jeang
Journal:  Pharm Res       Date:  2011-07-20       Impact factor: 4.200

7.  Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice.

Authors:  Annemart Koornneef; Piotr Maczuga; Richard van Logtenstein; Florie Borel; Bas Blits; Tita Ritsema; Sander van Deventer; Harald Petry; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2011-02-08       Impact factor: 11.454

8.  Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.

Authors:  Takashi Hirai; Mitsuhiro Enomoto; Hidetoshi Kaburagi; Shinichi Sotome; Kie Yoshida-Tanaka; Madoka Ukegawa; Hiroya Kuwahara; Mariko Yamamoto; Mio Tajiri; Haruka Miyata; Yukihiko Hirai; Makoto Tominaga; Kenichi Shinomiya; Hidehiro Mizusawa; Atsushi Okawa; Takanori Yokota
Journal:  Mol Ther       Date:  2013-10-28       Impact factor: 11.454

9.  pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.

Authors:  Ranadip Mandal; Monika Raab; Yves Matthess; Sven Becker; Rainald Knecht; Klaus Strebhardt
Journal:  Mol Oncol       Date:  2013-11-20       Impact factor: 6.603

10.  How to understand and outwit adaptation.

Authors:  Oliver Hoeller; Delquin Gong; Orion D Weiner
Journal:  Dev Cell       Date:  2014-03-31       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.